QUEBEC CITY, Nov. 7 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), alife sciences company commercializing high-value cancer diagnostic tests andspecialty laboratory services, today announced the publication of new dataregarding one of its proprietary prognostic tests for breast, colon andpotentially other cancers.
The October 1st issue of Clinical Cancer Research states that measuringp66 Shc tumor levels provides a unique and simple tool for stratifying stageIIA colon cancer patients by risk of recurrence and disease-specific death andmay assist in determining treatment strategies for these patients. The studyincluded 240 chemotherapy patients with stage IIA colon cancer. An analysis ofp66 Shc scores was found to be a significant prognostic indicator ofrelapse-free survival. DiagnoCure intends to conduct additional validatingclinical studies.
"These study results confirm that DiagnoCure's acquisition of the Shctests in August 2007 was directly in line with our strategic goal of creatinga suite of high-value tests that will aid in the diagnosis, prognosis/stagingand ultimately treatment decisions for patients with cancer" said JohnSchafer, President and CEO of DiagnoCure.
The Shc tests have the added potential to guide physician treatmentdecisions when used in conjunction with the Company's GC-C-based tests forcolorectal cancer, acquired earlier in 2007 and scheduled to launch from theCompany's CLIA-certified laboratory in 2008.
About Shc proteins
The potential clinical value of tests for Shc proteins have been studiedextensively in multiple clinical studies involving patients with five tumortypes, including breast and colon. Results have shown the tests to be strongindicators for a patient's risk of disease recurrence, as well as predictorsof response to certain cancer therapies, such as tamoxifen or traditionalchemotherapy. The tests measure the level of Shc proteins in tumor specimensremoved during surgery. The Shc proteins are involved in a number ofwell-documented cellular pathways that are correlated with tumoraggressiveness across many types of cancer, offering a broad opportunity forclinical testing. The study published in Clinical Cancer Research was led byDr. Steven Grossman, of the University of Massachusetts, and Dr. A. RaymondFrackelton Jr., Ph.D., of the Roger Williams Medical Center of Providence,Rhode Island.
DiagnoCure (TSX: CUR) is a life sciences company commercializinghigh-value cancer diagnostic tests and delivering lab services that increaseclinician and patient confidence in making critical treatment decisions.DiagnoCure is currently preparing to launch the first GC-C-based moleculartest for the management of colorectal cancer. In 2003, the Company enteredinto a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the developmentand commercialization of a second-generation test for PCA3, DiagnoCure'sproprietary genetic marker highly specific to prostate cancer. The test is nowavailable through laboratories in the U.S. using PCA3 analyte specificreagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)PCA3 in vitro assay. In addition to its own research, the Company intends toacquire or in-license additional promising cancer biomarkers from bothacademic and commercial institutions. For more information visitwww.diagnocure.com
This release contains forward-looking statements that involve known andunknown risks, uncertainties and assumptions that may cause actual results todiffer materially from those expected. By their very nature, forward-lookingstatements are based on expectations and hypotheses and also involve risks anduncertainties, known and unknown, many of which are beyond DiagnoCure'scontrol. As a result, investors are cautioned not to place undue reliance onthese forward-looking statements. The